Moderna Gains 9% On ESMO Congress Presentation Acceptance

Moderna Inc. (MRNA) stock rose 13.31% on FDA approvals for updated COVID-19 vaccines and positive oncology trial data. The company's revenue declined to $1.92B, with negative margins, but it holds $5.1B in cash. Analysts upgraded MRNA, citing its expanding mRNA product portfolio and potential peak sales of $9.2B in oncology.

Moderna's (MRNA) stock rose 9.4% after positive Phase 3 trial results for its cancer vaccine, sustained investor optimism, and FDA approval of its COVID-19 vaccines. The company also completed a $2.6B convertible note offering. MRNA shares are up 442% YTD, trading near their 52-week high.

Moderna's shares rose 9% after its Phase 3 melanoma study was selected for a Presidential Symposium at the European Society for Medical Oncology congress. Merck and BioNTech also saw gains. The stock is trading at $167.90. No new data was released, but the high-profile presentation is seen as a positive signal.

Moderna (MRNA) stock rose 9.3% to $168.36 after positive Phase 3 cancer vaccine data with Merck. Analysts upgraded the stock with new price targets. The broader market also gained, benefiting biotech stocks. FDA approvals and a $2.6B note offering supported the rally.

Moderna's mRNA-based flu vaccine, mFlusiva, is now available at U.S. pharmacies for adults 50+. FDA approved it, with Phase 3 trials showing 27% higher efficacy than standard vaccines. Priced around $171 per dose, coverage by insurers is uncertain. The vaccine targets flu only, not COVID-19.

Moderna's mRNA-based flu vaccine, mFlusiva, is now available at U.S. pharmacies like CVS for adults 50+. FDA approved it in August, with traditional and accelerated authorizations for different age groups. Clinical trials showed 27% higher efficacy than standard vaccines, with mild side effects. Costs around $171 per dose without insurance, coverage by insurers uncertain. Moderna's combined flu-COVID vaccine is not yet approved in the U.S.